Findings
========

Background
----------

There are genetic variations in genes encoding for the hepatic CYP450 metabolizing enzymes that can lead to undesirable drug reactions or inadequate response to commonly prescribed doses, either because of reduced or enhanced enzyme activity, respectively \[[@B1]\]. Testing for the activity of the CYP450 enzymes and isoforms before a patient receives a specific medication can provide valuable information concerning the initial dose. Molecular genetic testing is advantageous and more cost-effective compared to enzymatic methods due to methodological simplicity.

It is notable that in August 2007, the FDA label for warfarin, a frequently used anti-coagulant drug, was updated to highlight the benefit of genetic testing to predict warfarin response. This was renewed on February 2010 (<http://www.fda.gov/>). Candidate-gene association studies have identified two genes responsible for the main proportion of warfarin response: *CYP2C9*, which codes for the enzyme cytochrome CYP450 2C9 that metabolizes S-warfarin \[[@B2]\] and *VKORC1*, which codes for warfarin's target, vitamin K epoxide reductase \[[@B3]\]. *CYP2C9\*2* (Arg 144 to Cys) and *CYP2C9\*3* (Ile 359 to Leu) are recognized as the main *CYP2C9* variants in humans, affecting negatively the enzyme activity \[[@B4],[@B5]\]. In order to avoid high risk for bleeding, these polymorphisms must be taken into account before warfarin treatment \[[@B6]\]. Warfarin-dosing algorithms that incorporate *CYP2C9* and *VKORC1* genetic profile seem to predict pretty accurately the required warfarin dose for each patient \[[@B7],[@B8]\].

The *CYP3A5* gene represents the major extrahepatic isoform of CYP3A gene family and in association with *CYP3A4* are responsible for the metabolism of over 50% of all the clinically used drugs \[[@B9]\]. Some studies pay special attention at the frequent *CYP3A5\*3* allele and tacrolimus dosing \[[@B10]\], a frequently used immunosuppressant drug. It is recommended that homozygous *CYP3A5\*3/\*3* patients receive roughly a 50% lower initial tacrolimus dose than patients with at least one wild type *CYP3A5\*1* allele as a result of the difference observed in oral clearance \[[@B10],[@B11]\].

According to the available bibliography, it is more than evident that different human populations can differ significantly in genetic allelic frequencies for drug metabolism genes \[[@B12]\]. The purpose of the present study was to investigate for the first time the prevalence of the most common allelic variants of *VKORC1*, *CYP2C9* and *CYP3A5* in a representative sample of the Greek-Cypriot population, and to compare these data with existing published data from other populations.

Methods
-------

### Subjects

Genomic DNA isolated from whole peripheral blood \[[@B13]\] from 148 male healthy unrelated Greek-Cypriot subjects over 20 years old, was used for this study. The population of Greek-Cypriots is 660,000 (census of 2011), therefore the number of 148 individuals represents adequately our population. The subjects were selected according to their origin, aiming at even geographical coverage of all the provinces of Cyprus, including mountainous areas, thereby avoiding population stratification. We enrolled only male subjects for this study due to the fact we had more information about their geographic origin in contrast with females, because of their participation in another phylogenetics project. The DNA samples were used after they were anonymized. Our research project has been approved by the Cyprus National Bioethics Committee. Informed consent was obtained from all subjects. Research carried out on volunteers of this study was in compliance with the Helsinki Declaration.

Molecular genetic analysis
--------------------------

In this study we directly tested our sample group only for the four following genetic variants: *VKORC1* g.-1639G/A, *CYP2C9\*2*, *CYP2C9\*3* and *CYP3A5\*3*. We did not test specifically for the wild type *CYP2C9\*1* allele, the frequency of which was inferred from the absence of the two variants tested. The genetic polymorphisms were genotyped by PCR-RFLP assays. Details of the methods regarding the *VKORC1* g.-1639G/A, *CYP2C9\*2* and *CYP3A5\*3* polymorphisms are described elsewhere \[[@B14]-[@B16]\]. For the *CYP2C9\*3* polymorphism, the following primers were designed and used for amplification:

CYP2C9-3_For: 5' ACACAGATGCTGTGGTGCACGAGGTCCAGAG***G***TAC 3'

CYP2C9-3_Rev: 5' CTGGAAACAAGAGAAAGTCCAGTTAAACTGCCATAC 3'

The forward primer was modified by substitution of the fourth nucleotide from the 3' end, from A to G (italics and bold), so that upon amplification a restriction recognition site for *BanI* is created. The digestion products were analyzed by electrophoresis on 3.5% agarose gels. The *CYP2C9\*3* allele is represented by the 225 bp and 31 bp bands, whereas wild type allele is represented by the uncut 256 bp band.

### Statistical analysis

Comparison of population allele frequencies was performed through Pearson chi-square test, using SPSSv.15 statistical package (IBM, USA). The significance level, alpha, was set to 0.05. Hardy-Weinberg equilibrium was tested for all the analyzed polymorphisms through an Excel based application (Microsoft Office 2007).

Results and discussion
----------------------

Genotypic frequencies for the tested pharmacogenetics variants in our population are tabulated in Table [1](#T1){ref-type="table"}. The genotypic frequencies for each variant are in Hardy-Weinberg equilibrium. All the tested Greek-Cypriots are carriers of the *CYP3A5*\*3 allele (no homozygous wild-type *CYP3A5*\*1/\*1 were found), which is responsible for reduced tacrolimus clearance, while 88.5% of them are homozygous *CYP3A5*\*3/\*3 (Table [1](#T1){ref-type="table"}). These frequencies are very similar with those for the Hellenic population in Greece and generally with those for the Caucasian population \[[@B12],[@B17]\]. We paid special attention at genotypic combinations for the three genotyped warfarin related genes (Table [2](#T2){ref-type="table"}). We believe that clinicians in Cyprus have to take seriously into account that \~18% of the Greek-Cypriot population they serve are carriers of four or three risk alleles and about 50% carry at least two risk alleles, predisposing for bleeding after taking high warfarin doses. The combinatorial frequency of *CYP2C9* and *VKORC1* genotypes in the target population appears higher than expected based on individual genotypes, but we do not have a convincing explanation for this. Individuals carrying six or five risk alleles were not detected. Interestingly, we found that 2.7% of subjects in our population sample are simultaneously carriers for the three tested variants (Table [2](#T2){ref-type="table"}), a frequency that is exactly the same with what is reported in Jewish populations \[[@B18]\].

###### 

Genotype distribution of the four pharmacogenetics variants in the Greek-Cypriot population

         ***VKORC1*-1639AG**  ***CYP2C9***   ***CYP2C9***    ***CYP3A5***                                                   
  ----- --------------------- -------------- -------------- -------------- ------- ------ ------- ------- ---- ---- ------- -------
  148            44           70             34                  107       34      7        115   33      0     0   17      131
  100           29.7%         47.3%          23.0%              72.3%      23.0%   4.7%    77.7%  22.3%   0%    0%  11.5%   88.5%

###### 

Genotypic combinations of the three genotyped variants related with warfarin, in 148 Greek-Cypriot individuals

  **Genotypic combinations**   **No**                      **%**                             
  ---------------------------- --------------------------- ----------------- --------------- -------
  *VKORC1* -AA                 *CYP2C9*\*2/\*2             *CYP2C9*\*1/\*3   0               0
  *VKORC1* -AA                 *CYP2C9*\*2/\*2             *CYP2C9*\*1/\*1   2**\*\*\*\***   1.35
  *VKORC1* -AA                 *CYP2C9*\*1/\*2             *CYP2C9*\*1/\*3   2**\*\*\*\***   1.35
  *VKORC1* -AG                 *CYP2C9*\*1/\*2             *CYP2C9*\*1/\*3   2**\*\*\***     1.35
  *VKORC1* -AG                 *CYP2C9*\*2/\*2             *CYP2C9*\*1/\*1   3**\*\*\***     2.03
  *VKORC1* -AA                 *CYP2C9*\*1/\*2             *CYP2C9*\*1/\*1   7**\*\*\***     4.73
  *VKORC1* -AA                 *CYP2C9*\*1/\*1             *CYP2C9*\*1/\*3   10**\*\*\***    6.76
  *VKORC1* -AG + GG            *CYP2C9*\*1/\*1             *CYP2C9*\*1/\*3   19              12.84
  *VKORC1* -AA                 *CYP2C9*\*1/\*1             *CYP2C9*\*1/\*1   23              15.54
  *VKORC1* -AG + GG            *CYP2C9*\*1/\*2 + \*2/\*2   *CYP2C9*\*1/\*1   25              16.89
  *VKORC1* -AG + GG            *CYP2C9*\*1/\*1             *CYP2C9*\*1/\*1   55              37.16
  SUM                          148                         100                               

No CYP2C9\*3/\*3 genotypes were observed.

**\*\*\*\***Individuals with four risk alleles (2.70%).

**\*\*\***Individuals with three risk alleles (14.87%).

It has been proven that *CYP2C9\*2* and \*3 cause a reduction in S-warfarin clearance (10-fold variation observed from *CYP2C9\*11* to *CYP2C9\*33*) activity (\*1/\*1 \> \*1/\*2 \> \*1/\*3 \> \*2/\*2 \> \*2/\*3 \> \*3/\*3). The effect of the *CYP2C9\*3/\*3* genotype is the most severe one with clearance of S-warfarin being 10% of the wild type genotype \[[@B19]\]. *VKORC1* encoded enzyme interacts with warfarin, so the enzyme levels can affect sensitivity to warfarin. Jorgensen et al. \[[@B20]\], reviewed recently almost all the available bibliography and found that *CYP2C9\*3* and *VKORC1* variants are significant for warfarin dose determination for most ethnic populations \[[@B20]\]. Sconce et al. \[[@B7]\] showed clearly (giving also a useful algorithm for warfarin dose determination) that the three significant variants of the aforementioned genes have additive properties \[[@B7]\].

In conclusion, it is evident through population specific studies, like the one we present here, that pharmacogenetics allele frequencies can differ significantly in different sub-populations. The results of our study compare well to those of other Caucasian populations, but with some notable differences, like the increased frequency of the *VKORC1-*1639A allele (Table [3](#T3){ref-type="table"}). Allele frequencies between the six provinces of Cyprus show high similarity (Table [3](#T3){ref-type="table"}). We must have in mind that the Greek-Cypriot population used to be isolated and small, and therefore susceptible to migratory waves and genetic drift phenomena. Even comparing with the Greek population of Greece, that we are closely related (geographically and culturally), there are still some significant differences (Table [3](#T3){ref-type="table"}). This fact underlines the necessity for population-specific allelic frequency studies, since these determinations can be helpful for the prescribing clinicians and their patients.

###### 

Allele frequencies of the four studied pharmacogenetic variants in Cyprus and comparison with other populations

  **Population group**   **No of tested chromosomes**   ***VKORC1*-1639A**   ***CYP2C9*\*2**   ***CYP2C9*\*3**   ***CYP3A5*\*3**   **Reference**
  ---------------------- ------------------------------ -------------------- ----------------- ----------------- ----------------- ---------------
  **Greek-Cypriots**     **296**                        **53.38%**           **16.20%**        **11.15%**        **94.26%**        This study
  Nicosia                106                            62.26%               18.87%            9.43%             95.28%            
  Limassol               52                             44.23%               19.23%            11.54%            96.15%            
  Ammochostos            60                             51.67%               15.00%            15.00%            93.33%            
  Larnaka                28                             50.00%               14.29%            7.14%             92.86%            
  Pafos                  32                             50.00%               9.38%             9.38%             90.63%            
  Kerynia                18                             44.44%               11.11%            16.67%            94.44%             
  Caucasians             1362                           37.81%                                                                     \[[@B21]\]
                         (P \< 0.001)                                                                                              
  3484                                                  14.00%               6.40%                               \[[@B12]\]        
                                                        (P = 0.296)          (P = 0.002)                                           
  284                                                                                          95.50%            \[[@B12]\]        
                                                                                                                 (P = 0.526)        
  Africans               736                            10.05%                                                                     \[[@B21]\]
                         (P \< 0.001)                                                                                              
  1376                                                  2.20%                1.80%                               \[[@B12]\]        
                                                        (P \< 0.0001)        (P \< 0.001)                                          
  1330                                                                                         31.80%            \[[@B12]\]        
                                                                                                                 (P \< 0.001)       
  Eastern Asians         1282                           91.03%                                                                     \[[@B21]\]
                         (P \< 0.001)                                                                                              
  13284                                                 \<0.1%               3.30%                               \[[@B12]\]        
                                                        (P \< 0.001)         (P \< 0.001)                                          
  7658                                                                                         76.10%            \[[@B12]\]        
                                                                                                                 (P \< 0.001)       
  Hellenes from Greece   656                            44.40%                                                                     \[[@B22]\]
                         (P = 0.010)                                                                                               
  566                                                   12.90%               8.13%             94.35%            \[[@B17]\]        
                                                                             (P = 0.183)       (P = 0.144)       (P = 0.957)        

In parenthesis: p-value after comparison with the Greek-Cypriot frequencies.
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